Oramed Pharmaceuticals Inc. (ORMP) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-26

How it makes money

It currently earns by providing loans to other companies and collecting interest and fees on those financial assets.

While the company describes itself as a pharmaceutical developer, its recent financial history shows it acting as a lender to other entities, specifically Scilex, earning income through interest payments and potential asset appreciation from warrants and equity stakes.

What protects it: the moat

Management claims to protect its core technology through patents, though it lacks proven commercial success.

The company relies on intellectual property laws to defend its oral protein delivery platform. However, it admits it may be unable to enforce these rights effectively against competitors.

What growth costs

It incurs significant research and development costs to maintain its pharmaceutical pipeline while managing the capital requirements of its investment portfolio.

The filing does not provide specific figures for capital expenditures, but notes that the business is characterized by high R&D spending and the need for ongoing funding to support its clinical trials and investment activities.

What could damage it

The company's earnings are highly vulnerable to the default of its corporate borrowers.

Because a significant portion of its financial health is tied to the repayment of loans by entities like Scilex, any inability of those borrowers to service their debt would result in a material loss of income and impaired capital.

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Other companies in Biotechnology